New York, New York--(Newsfile Corp. - August 12, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Ardelyx, Inc. (NASDAQ: ARDX).
CLICK HERE FOR MORE DETAILS:
https://claimyourloss.com/securities/ardelyx-inc-loss-submission-form/?id=18495&from=5
Affected shareholders purchased shares of ARDX between August 6, 2020 and July 19, 2021
Shareholders interested in representing the class of wronged shareholders have until September 28, 2021 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
According to a filed complaint, Ardelyx, Inc. issued materially false and/or misleading statements and/or failed to disclose that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/92967
